Bafna Pharmaceuticals Limited
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Bafna Pharmaceuticals Limited's yearly results (2023–2026), compared with Healthcare companies in India. Tap ? on any ratio for what it means.
What stands out
- Profit Cash Ratio: Over the last 3 years, every ₹100 of reported profit came with ₹208 of operating cash. Higher than 88% of Healthcare companies in India.
- Growth Efficiency Ratio: Sales grew 31% in 3 years, but profit fell: ₹1 less profit per ₹100 of extra sales. Lower than 85% of Healthcare companies in India.
Where ₹100 of sales goes
Latest year (Mar 2026). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
₹208Over the last 3 years, every ₹100 of reported profit came with ₹208 of operating cash.
Higher than 88% of Healthcare companies in India.
Self-Funding Ratio
0.8×Over the last 3 years its own operating cash paid for 75% of its investment spending (capex); the rest came from other sources such as borrowing, cash reserves or new shares.
Lower than 74% of Healthcare companies in India.
Cash Locked Ratio
₹25For every ₹100 of sales, ₹25 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against ₹28 tied up three years earlier.
More money tied up than 53% of Healthcare companies in India.
Growth quality
Steadiness Ratio
2/3 · 1/3Sales grew in 2 of the last 3 years; profit grew in 1 of 3.
Less steady than 84% of Healthcare companies in India.
Growth Efficiency Ratio
−₹1Sales grew 31% in 3 years, but profit fell: ₹1 less profit per ₹100 of extra sales.
Lower than 85% of Healthcare companies in India.
Asset Productivity Ratio
+31% / +35%In 3 years sales changed by +31% while total assets changed by +35%. Both moved at about the same pace.
Balance-sheet strength
Debt Due Cover Ratio
0.8×Debt due within a year is covered 0.8 times by its yearly operating cash.
Lower than 61% of Healthcare companies in India.
Cash Cushion Ratio
−3%Debt, after subtracting cash, equals 3% of its market value (net debt).
Lower than 57% of Healthcare companies in India.
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (14)
Bafna Pharmaceuticals Limited owes ₹0.45 for every ₹1 it owns. Net profit rose 167% in the year to Mar 2026, and shrank 1% a year on average over 3 years.
Compared with Healthcare companies in India · latest annual results Mar 2026.
P/E ratio
134.6Investors pay ₹134.6 for every ₹1 of Bafna Pharmaceuticals Limited's yearly profit, higher than 95% of Healthcare companies in India.
P/B ratio
10.90The share price is 10.90 times Bafna Pharmaceuticals Limited's book value per share, higher than 83% of Healthcare companies in India.
Market cap
₹1,048 CrThe total market value of all of Bafna Pharmaceuticals Limited's shares at today's price (share price × number of shares), smaller than 80% of Healthcare companies in India. PosiCap size class: Mini Cap.
Net worth (book value)
₹96 CrWhat Bafna Pharmaceuticals Limited would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (31 Mar 2026).
Book value per share
₹40.64Net worth divided by the number of shares. The share price of ₹442.95 is 10.9 times this, which is the P/B above.
Return on equity (ROE)
8.1%Bafna Pharmaceuticals Limited earned 8.1% on its shareholders' money over the last year, lower than 75% of Healthcare companies in India.
Owes vs Owns
0.45×Bafna Pharmaceuticals Limited owes ₹0.45 for every ₹1 it owns (low), higher than 72% of Healthcare companies in India.
Dividend yield
NoneBafna Pharmaceuticals Limited does not currently pay a dividend.
Revenue growth
+3%Revenue rose 3% in the year to Mar 2026, and grew 9% a year on average over 3 years.
Profit growth
+167%Net profit rose 167% in the year to Mar 2026, and shrank 1% a year on average over 3 years.
Profit margin
7.4%Bafna Pharmaceuticals Limited keeps ₹7 of every ₹100 of revenue as net profit.
Cash quality
1.4×Cash from Bafna Pharmaceuticals Limited's business was 1.4× its reported profit in the year to Mar 2026 — its profit turned into cash.
Interest cover
3.0×Bafna Pharmaceuticals Limited's operating profit covered its interest costs 3.0 times in the year to Mar 2026.
Cash vs debt
Net debtBafna Pharmaceuticals Limited had ₹35 Cr more debt than cash (net debt) at Mar 2026.
Questions
What is Bafna Pharmaceuticals Limited's P/E ratio?
Investors pay ₹134.6 for every ₹1 of Bafna Pharmaceuticals Limited's yearly profit, higher than 95% of Healthcare companies in India.
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Bafna Pharmaceuticals Limited: ₹1,048 Cr ÷ ₹96 Cr (31 Mar 2026) = 10.9.
What is Bafna Pharmaceuticals Limited's return on equity?
Bafna Pharmaceuticals Limited earned 8.1% on its shareholders' money over the last year, lower than 75% of Healthcare companies in India.
How much does Bafna Pharmaceuticals Limited owe compared with what it owns?
Bafna Pharmaceuticals Limited owes ₹0.45 for every ₹1 it owns (low), higher than 72% of Healthcare companies in India.
Does Bafna Pharmaceuticals Limited pay a dividend?
No. Bafna Pharmaceuticals Limited does not currently pay a dividend.
Is Bafna Pharmaceuticals Limited's revenue growing?
Revenue rose 3% in the year to Mar 2026, and grew 9% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.